B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GAPDH

MOLECULAR TARGET

glyceraldehyde-3-phosphate dehydrogenase

UniProt: P04406NCBI Gene: 259724 compounds

GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is targeted by 24 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GAPDH

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Azacitidine1.393
2Azacitidine1.393
3Epinephrine1.393
4Berberine1.102
5plumbagin [Supplementary Concept]1.102
6Vitamin K 31.102
7caffeic acid0.691
8Catechin0.691
9Rosmarinic Acid0.691
10Vitamin K 20.691
11Carbazilquinone0.691
12salvin [Supplementary Concept]0.691
13Dactinomycin0.691
14Dihydroxyphenylalanine0.691
15Ergosterol0.691
16Ethidium0.691
17Fusaric Acid0.691
1819-((1'S,4'R)-4'-hydroxy-1'-methoxy-2'-oxopentyl)geldanamycin [Supplementary Concept]0.691
19Lovastatin0.691
20Methyldopa0.691
21Norepinephrine Precursor of epinephrine that is secreted by0.691
22Oxcarbazepine0.691
23Pioglitazone0.691
24streptonigrin0.691

About GAPDH as a Drug Target

GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 24 compounds with documented GAPDH interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GAPDH inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.